Both ABP-671 and ABP-745 have the potential to give gout patients more effective and safer alternatives to existing gout therapies.

FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers.

The Phase III placebo-controlled, randomised, double-blind study is evaluating ADX-324's efficacy in adults with HAE.

The event will take place on November 3, 2025 beginning at 10 am ET and will feature presentations by ProQR Management and ...

BlossomHill Therapeutics, Inc., a privately-held, a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today presented preliminary ...

Positive Results from Clinical Pharmacokinetic Study for the Eosinophilic Esophagitis Specific Formulation with the Drug Candidate AQ280Aqilion today announces positive results from the ARIA-2 ...

Simulations Plus ( ($SLP) ) has shared an announcement. On October 22, 2025, Simulations Plus announced its preliminary fiscal year 2025 results ...

Enrollment for this Phase 3 program follows positive Phase 1/2 data demonstrating that ADX-324 achieved significant and durable suppression of prekallikrein (PKK) protein levels with a favorable ...

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and ...

Detailed price information for Rapt Therapeutics Inc (RAPT-Q) from The Globe and Mail including charting and trades.